VASTHERA Co., Ltd
June 16, 2025
Company Presentation
Cardiovascular
Vasthera Co., Ltd. is a Korea-based pre-clinical stage pharmaceutical company pioneering first-in-class drugs for chronic inflammatory diseases, such as cardiovascular, cancer, eye, and neurodegenerative diseases, through innovative platforms, 'Redoxizyme' and 'ATGen,' which generate small molecules that target redox and autophagy (ATG) signaling pathways critical for the onset and pathogenesis of these diseases.
Company HQ City:
Seoul
Company HQ Country:
Korea, Republic of
Year Founded:
2018
Lead Product in Development:
VTB-10 for pulmonary arterial hypertension will enter phase 1 trials this year.
CEO
Sang Won Kang, PhD
Year Founded
2018
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
3
When you expect your next catalyst update?
The company is currently undergoing due diligence for a partnership (L/O) agreement, with strong prospects for closing the deal by the end of this year. This partnership could significantly enhance the company’s strategic position and drive future growth. Additionally, the Phase 1 clinical trial for VTB-10 is progressing well, with results expected by June next year. Positive data from this trial could serve as a major value inflection point, paving the way for further clinical development and potential commercialization.
What is your next catalyst (value inflection) update?
December 2025
Website
http://vasthera.com/
Primary Speaker
)
)
)
)
){kind=logo}
)
){kind=logo}